

A Prospective Randomised Comparison of CMF versus Sequential Epirubicin Followed by CMF as Adjuvant Chemotherapy for Women with Early Breast Cancer

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 08/10/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/national-breast-cancer-study-of-epirubicin-as-adjuvant-therapy>

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number

BR9601

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Breast cancer

Interventions

1. Group A: Chemotherapy, cyclophosphamide, methotrexate and 5-fluorouracil (CMF) repeated every 3 weeks for eight cycles
2. Group B: Chemotherapy, epirubicin repeated every 3 weeks for four cycles followed by CMF repeated every 3 weeks for four cycles

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/04/2001

Eligibility

Key inclusion criteria

1. Histologically confirmed breast cancer
2. Histologically confirmed axillary node metastases

3. Fit to receive chemotherapy on either arm of the trial
4. Adequate hepatic, renal and bone marrow function
5. No previous chemotherapy
6. No prior or concomitant malignancy, except basal cell carcinoma or in situ carcinoma of the cervix
7. No bilateral breast tumours or locally advanced or metastatic breast cancer, including supraclavicular fossa metastases

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2000

Date of final enrolment

30/04/2001

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Pharmacia Ltd & Upjohn (UK)

ROR

<https://ror.org/04x4v8p40>

Funder(s)

Funder type

Industry

Funder Name

Pharmacia and Upjohn (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	02/11/2006		Yes	No